InspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017

Completes Transition to Local Distribution Network Across Europe

 CGuard Sales in European Countries Transitioned Back from Former Distributor Increase 122% Versus Q1 2017

Tel Aviv—August 8, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today provided a business update, including the successful transition of all territories previously covered by the Company’s former European distributor to a local network of regional distributors.  The Company also reported financial and operating results for the second quarter ended June 30, 2017.

James Barry, PhD, Chief Executive Officer of InspireMD, commented, “I am pleased to report we successfully completed our transition from a single distributor covering 18 European countries, to now having a direct distribution model with local distributors that have much greater reach into all the relevant clinical specialties and each of their respective markets. Our new distributors share our belief that CGuard™ can achieve market leadership in all countries where it is available.  Moreover, we completed the rollout on schedule and there has been tremendous support from the top key opinion leaders (KOL) in each of these markets.  In fact, CGuard sales in these specific European countries increased 122% sequentially versus the first quarter of 2017.”

“With our European distribution network in place, we are now focusing our efforts on expansion into other markets around the world.  Most recently, we signed an agreement with a leading distributor in Taiwan.  This follows a similar agreement in Hong Kong earlier this year, and we are in talks with a number of distributors across Asia to further expand our footprint. We expect to make additional announcements on this subject in the coming months.  We also announced recent agreements in Peru and Ecuador, and our plan is to continue to expand our presence in Central and South America. CGuard™ is a platform technology that can be transferred to a number of other products, and building this global distributor network should allow us to launch new products quickly and efficiently as our pipeline develops over the coming years.”

“We also continue to report new data and are gaining significant attention from top KOLs around the world. In May, we reported publication of the investigator initiated IRON-GUARD Italian clinical registry in the peer reviewed journal EuroIntervention.  IRON-GUARD was an independent, multicenter, multi-disciplinary clinical study treating patients with carotid artery disease using the CGuard™ EPS in 12 Italian centers. The IRON-GUARD registry enrolled 200 patients, and showed results of 100% technical success placing the device, and zero incidence of major adverse cardiovascular events (MACE), comprised of death, major stroke or myocardial infarction, in all patients at 30 days.  Also in May, we were honored to have the team of Professor Alberto Cremonesi, Chief of the Cardiovascular Department and Director of the Interventional Cardiovascular Unit of Maria Cecilia Hospital – GVM Care & Research, Cotignola (Italy), perform a live endovascular interventional procedure featuring the CGuard™ EPS Carotid Stent at EuroPCR 2017.  The case was transmitted real time to the entire congress. EuroPCR is the world’s leading course in interventional cardiovascular medicine bringing together over 12,000 clinicians and industry executives each year.”

Dr. Barry concluded, “We remain extremely encouraged by the favorable response from leading medical practitioners around the world. Now that we have a robust distribution network in place across Europe, we believe we have a highly scalable and cost-effective platform to grow sales.  We plan to replicate this model around the world.  Overall, we achieved solid double-digit year-over-year and sequential revenue growth, which we expect to continue in the second half of the year.  We also remain focused on carefully managing expenses and driving shareholder value.  We appreciate the patience and support of our shareholders, and look forward to announcing additional significant milestones in the months ahead.”

Financial Results

Revenue for the second quarter ended June 30, 2017 was $640,000 compared to $540,000 during the same period in 2016. The increase was primarily due to an increase in sales of CGuard™ EPS as we entered new regional markets during the transition from our prior exclusive distribution partner for most of Europe.  The transition to local distributors reflects an effort to broaden our sales efforts from only interventional neuroradiologists to include vascular surgeons, interventional cardiologists and interventional radiologists, as well. In addition to the increase in sales of CGuard™ EPS, sales of MGuard™ Prime EPS slightly increased, as well.  Total operating expenses for the quarter ended June 30, 2017 were $2,441,000, an increase of 33.5% compared to $1,828,000 for the same period in 2016. This increase was primarily due to an increase in sales and marketing expenses (primarily to support the commercialization of CGuard™ EPS), as well as an increase in salary expenses primarily due to a non-cash accrual adjustment. Net loss for the quarter ended June 30, 2017 totaled $2,294,000, or $0.21 per basic and diluted share, compared to a net loss of $1,946,000, or $4.56 per basic and diluted share, in the same period in 2016.

Revenue for the six months ended June 30, 2017 was $1,209,000 compared to $1,103,000 during the same period in 2016. The increase was predominantly driven by the increase in sales of CGuard™ EPS offset by a decrease in sales of MGuard™ Prime EPS associated with the trend of doctors increasingly using drug eluting stents (DES) rather than bare metal stents in STEMI patients.  Total operating expenses for the six months ended June 30, 2017 were $4,919,000, an increase of 25.4% compared to $3,924,000 for the same period in 2016. This increase was primarily due to an increase in sales and marketing expenses (primarily to support the commercialization of CGuard™ EPS), as well as an increase in salary expenses primarily due to a non-cash accrual. Net loss for the six months ended June 30, 2017 totaled $4,853,000, or $0.73 per basic and diluted share, compared to a net loss of $4,198,000, or $11.21 per basic and diluted share, in the same period in 2016.

As of June 30, 2017, cash and cash equivalents were $6,879,000, compared to $7,516,000 as of December 31, 2016.

Conference Call

The Company will host a conference call on Wednesday, August 9 at 8:00 a.m. Eastern Time. The conference call will be available via telephone by dialing toll free 866-682-6100 for U.S. callers or +1 862-255-5401 for international callers, or on the Company’s Investor Relations section of the website: http://www.inspiremd.com/en/investors/investor-relations/.

A webcast will also be archived on the Company’s website and a telephone replay of the call will be available approximately one hour following the call, through midnight August 23, 2017, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 15963.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants are quoted on the NYSE MKT under the ticker symbol NSPR.WS.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: craigs@inspiremd.com   

 

Crescendo Communications, LLC

David Waldman

Phone: (212) 671-1021

Email: NSPR@crescendo-ir.com

 

CONSOLIDATED STATEMENTS OF OPERATIONS (1)

 

(U.S. dollars in thousands, except per share data)

 

 

 

 

Six months ended

 

 

 

Three months ended

 

 

June 30,

 

June 30,

 

 

2017

 

2016

 

2017

 

2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

$640

 

$540

 

$1,209

 

$1,103

 

Cost of revenues

493

 

478

 

988

 

975

 

 

 

 

 

 

 

 

 

 

Gross Profit

147

 

62

 

221

 

128

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

Research and development

403

 

278

 

753

 

657

 

Selling and marketing

632

 

403

 

1,164

 

768

 

General and administrative

1,406

 

1,147

 

3,002

 

2,499

 

 

 

 

 

 

 

 

 

 

Total operating expenses

2,441

 

1,828

 

4,919

 

3,924

 

 

 

 

 

 

 

 

 

 

Loss from operations

(2,294)

 

(1,766)

 

(4,698)

 

(3,796)

 

 

 

 

 

 

 

 

 

 

Financial expenses

 

180

 

154

 

401

 

 

 

 

 

 

 

 

 

 

Loss before tax expenses

(2,294)

 

(1,946)

 

(4,852)

 

(4,197)

 

 

 

 

 

 

 

 

 

 

Tax expenses (Income)

 

 

1

 

1

 

 

 

 

 

 

 

 

 

 

Net Loss

$(2,294)

 

$(1,946)

 

$(4,853)

 

$(4,198)

 

 

 

 

 

 

 

 

 

 

Net loss per share – basic and diluted

$(0.21)

 

$(4.56)

 

$(0.73)

 

$(11.21)

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares of common stock used in computing net loss per share – basic and diluted

10,983,402

 

426,976

 

7,484,399

 

374,330

 

                       

 

 

 

 

CONSOLIDATED BALANCE SHEETS (2)

(U.S. dollars in thousands)

ASSETS

June 30,

 

December 31,

2017

 

2016

 

 

 

 

Current Assets:

 

 

 

Cash and cash equivalents

$6,879

 

$7,516

Accounts receivable:

 

 

 

     Trade, net

451

 

356

     Other

161

 

157

Prepaid expenses

73

 

65

Inventory

429

 

500

 

 

 

 

Total current assets

7,993

 

8,594

 

 

 

 

 

 

 

 

Non-current assets:

 

Property, plant and equipment, net

459

 

379

Funds in respect of employee rights upon retirement

430

 

399

Royalties buyout

25

 

38

 

 

 

 

Total non-current assets

914

 

816

 

 

 

 

Total assets

$8,907

 

$9,410

 

 

 

LIABILITIES AND EQUITY

June 30,

 

December 31,

2017

 

2016

 

 

 

 

Current liabilities:

 

 

 

Current maturity of long-term loan

$-

 

$2,680

Accounts payable and accruals:

 

 

 

     Trade

473

 

618

     Other

2,066

 

1,447

Advanced payment from customers

54

 

33

 

 

 

 

Total current liabilities

2,593

 

4,778

 

 

 

 

 

 

 

 

Long-term liabilities

 

 

 

Liability for employees rights upon retirement

572

 

587

 

 

 

 

Total long-term liabilities

572

 

587

 

 

 

 

 

 

 

 

Total liabilities

3,165

 

5,365

 

 

 

 

Equity:

 

 

 

Common stock, par value $0.0001 per share; 150,000,000 shares authorized at June 30, 2017 and December 31, 2016; 7,467,646 and 1,475,318 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively

1

 

Preferred B shares, par value $0.0001 per share;

500,000 shares authorized at June 30, 2017 and December 31, 2016; 181,295 and 311,521 shares issued and outstanding at June 30, 2017 and  December 31, 2016, respectively

 

Preferred C shares, par value $0.0001 per share;

1,172,000 shares authorized at June 30, 2017 ; 745,775 shares issued and outstanding at June 30, 2017

 

Additional paid-in capital

142,508

 

135,959

Accumulated deficit

(136,767)

 

(131,914)

 

 

 

 

Total equity

5,742

 

4,045

 

 

 

 

Total liabilities and equity

$8,907

 

$9,410

 

 

 

 

 

 

 

(1) All 2017 financial information is derived from the Company’s 2017 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission, all 2016 financial information is derived from the Company’s 2016 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission.

 

(2) All June 30, 2017 financial information is derived from the Company’s 2017 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission. All December 31, 2016 financial information is derived from the Company’s 2016 audited financial statements as disclosed in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2016 filed with the Securities and Exchange Commission.